By Julie Zhu and Kevin Huang HONG KONG/BEIJING (Reuters) -China is in talks with Pfizer Inc to secure a licence that will allow domestic drugmakers to manufacture and distribute a generic version of the U.S. firm’s COVID-19 antiviral drug Paxlovid in China, three sources told Reuters. China’s medical products regulator – the National Medical Products Administration (NMPA) – has been leading the talks with Pfizer since late last month, one of the sources with knowledge of the matter said. Beijing is keen to finalise licensing deal terms before the Lunar New Year which begins on Jan. 22, the sou…